This Cochrane Kidney and Transplant review from 2015 evaluates how corticosteroids treatment might be safely and most effectively used to treat steroid-sensitive nephrotic syndrome in children.

There have been three previous overviews of the evidence in 2000, 2005, and 2007 which showed that a longer duration of prednisone treatment up to seven months (3 to 7 months) better prevented disease relapse and helped children avoid frequent relapses after their first episode of nephrotic syndrome than shorter courses (2-3 months). Recently, new trials have contradicted this evidence by showing no benefit of prolonging prednisone treatment beyond 2-3 months.

To address this conflict in the existing information and to evaluate other treatment strategies, this is an updated evidence strategy combining earlier studies of corticosteroids with 10 newer trials to include 34 studies involving 3000 children.

CLICK HERE to access the webinar.